LAV GP V, L.P. - Net Worth and Insider Trading

LAV GP V, L.P. Net Worth

The estimated net worth of LAV GP V, L.P. is at least $97 Million dollars as of 2025-05-04. LAV GP V, L.P. is the 2201 Interest of corporation controlled by you of ImmuneOnco Biopharmaceuticals (Shanghai) Inc and owns about 15,178,770 shares of ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) stock worth over $97 Million. Details can be seen in LAV GP V, L.P.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that LAV GP V, L.P. has not made any transactions after 2023-09-05 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of LAV GP V, L.P.

LAV GP V, L.P. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, LAV GP V, L.P. owns 1 companies in total, including ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) .

Click here to see the complete history of LAV GP V, L.P.’s form 4 insider trades.

Insider Ownership Summary of LAV GP V, L.P.

Ticker	Company	Transaction Date	Type of Owner
HKSE:01541	ImmuneOnco Biopharmaceuticals (Shanghai) Inc	2023-09-05	2201 Interest of corporation controlled by you

LAV GP V, L.P. Latest Holdings Summary

LAV GP V, L.P. currently owns a total of 1 stock. LAV GP V, L.P. owns 15,178,770 shares of ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) as of September 5, 2023, with a value of $97 Million.

Latest Holdings of LAV GP V, L.P.

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
HKSE:01541	ImmuneOnco Biopharmaceuticals (Shanghai) Inc	2023-09-05	15,178,770	6.37	96,688,765

Holding Weightings of LAV GP V, L.P.

LAV GP V, L.P. Form 4 Trading Tracker

According to the SEC Form 4 filings, LAV GP V, L.P. has made a total of 1 transactions in ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) over the past 5 years, including 0 buys and 0 sells. The most-recent trade in ImmuneOnco Biopharmaceuticals (Shanghai) Inc is the sale of 15,178,770 shares on September 5, 2023, which brought LAV GP V, L.P. around $0.

Insider Trading History of LAV GP V, L.P.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

LAV GP V, L.P. Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

LAV GP V, L.P. Ownership Network

Ownership Network List of LAV GP V, L.P.

No Data

Ownership Network Relation of LAV GP V, L.P.

LAV GP V, L.P. Owned Company Details

What does ImmuneOnco Biopharmaceuticals (Shanghai) Inc do?

Who are the key executives at ImmuneOnco Biopharmaceuticals (Shanghai) Inc?

LAV GP V, L.P. is the 2201 Interest of corporation controlled by you of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. Other key executives at ImmuneOnco Biopharmaceuticals (Shanghai) Inc include 2501 Other Tian Wenzhi , 2201 Interest of corporation controlled by you Yu Xiaoyong , and 2101 Beneficial owner shang hai zhang ke ling yi sheng fan chuang ye tou zi zhong xin you xian he huo .

ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) Insider Trades Summary

Over the past 18 months, LAV GP V, L.P. made no insider transaction in ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541). Other recent insider transactions involving ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) include a net purchase of 150,000 shares made by Tian Wenzhi , a net sale of 3,165,000 shares made by shang hai zhang ke ling yi sheng fan chuang ye tou zi zhong xin you xian he huo , and a net sale of 0 shares made by shang hai zhang jiang ke ji chuang ye tou zi you xian gong si .

In summary, during the past 3 months, insiders sold 0 shares of ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) in total and bought 150,000 shares, with a net purchase of 150,000 shares. During the past 18 months, 3,165,000 shares of ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) were sold and 150,000 shares were bought by its insiders, resulting in a net sale of 3,015,000 shares.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541)'s detailed insider trading history can be found in Insider Trading Tracker table.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Insider Transactions

No Available Data

LAV GP V, L.P. Mailing Address

Above is the net worth, insider trading, and ownership report for LAV GP V, L.P.. Currently GuruFocus does not have mailing address information for LAV GP V, L.P..

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.